Stoke Therapeutics (STOK) Projected to Post Earnings on Thursday

Stoke Therapeutics (NASDAQ:STOK) is anticipated to post its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Stoke Therapeutics to post earnings of ($0.80) per share and revenue of $6.4830 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, March 16th. The company reported ($0.97) earnings per share for the quarter. The firm had revenue of $1.40 million during the quarter. Stoke Therapeutics had a negative net margin of 3.73% and a negative return on equity of 2.05%. On average, analysts expect Stoke Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Stoke Therapeutics Trading Down 3.7%

Stoke Therapeutics stock traded down $1.28 during midday trading on Tuesday, hitting $32.91. The stock had a trading volume of 101,648 shares, compared to its average volume of 728,018. The stock has a market cap of $2.05 billion, a P/E ratio of -274.31 and a beta of 1.20. Stoke Therapeutics has a 12 month low of $8.30 and a 12 month high of $40.22. The business has a fifty day moving average price of $34.48 and a 200 day moving average price of $32.06.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Guggenheim assumed coverage on Stoke Therapeutics in a report on Thursday, February 5th. They issued a “buy” rating and a $60.00 price objective for the company. Chardan Capital reissued a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 18th. Wall Street Zen lowered Stoke Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Wolfe Research assumed coverage on Stoke Therapeutics in a report on Monday, February 23rd. They issued an “outperform” rating and a $40.00 price objective for the company. Finally, Needham & Company LLC boosted their price objective on Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $41.83.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 6,686 shares of the business’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total transaction of $209,539.24. Following the completion of the transaction, the insider directly owned 40,798 shares in the company, valued at approximately $1,278,609.32. The trade was a 14.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, General Counsel Jonathan Allan sold 4,628 shares of the business’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $145,041.52. Following the transaction, the general counsel owned 28,836 shares of the company’s stock, valued at approximately $903,720.24. This represents a 13.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 69,699 shares of company stock valued at $2,526,714. 9.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in STOK. Kestra Advisory Services LLC acquired a new position in shares of Stoke Therapeutics during the fourth quarter worth approximately $26,000. BNP Paribas Financial Markets boosted its position in shares of Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after buying an additional 1,668 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Stoke Therapeutics by 461.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after buying an additional 3,591 shares during the period. Osaic Holdings Inc. boosted its position in shares of Stoke Therapeutics by 263.3% during the second quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock worth $85,000 after buying an additional 5,427 shares during the period. Finally, Persistent Asset Partners Ltd acquired a new position in shares of Stoke Therapeutics during the fourth quarter worth approximately $145,000.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.